241 filings
8-K
XCUR
Exicure Inc
22 Apr 24
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
4:20pm
NT 10-K
XCUR
Exicure Inc
1 Apr 24
Notice of late annual filing
4:20pm
8-K
XCUR
Exicure Inc
5 Feb 24
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
4:16pm
8-K
XCUR
Exicure Inc
16 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:16pm
8-K
XCUR
Exicure Inc
1 Dec 23
Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review
4:21pm
8-K
mk8h 8jo2he
28 Nov 23
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
4:19pm
NT 10-Q
mbc oslk4w
14 Nov 23
Notice of late quarterly filing
4:28pm
8-K
z2quu40k
6 Oct 23
Other Events
5:03pm
8-K
vzfx5
27 Sep 23
Departure of Directors or Certain Officers
5:25pm
8-K
6xboa6a4udybmrm
13 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:03pm
8-K
4sn7rl
23 Aug 23
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
9:29am
8-K
y4fqupu
11 Aug 23
Exicure, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:18pm
8-K
xteh7mbrs6469dbq5d
9 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:24pm
8-K
gjgmav7yf w6ncn
4 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:23pm
8-K
m1apbw2p3zulse
14 Jul 23
Exicure, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:05pm
8-K
03uqw44m9yss 2w1
14 Jun 23
Departure of Directors or Certain Officers
4:46pm
8-K
23x2q65q
6 Jun 23
Changes in Registrant's Certifying Accountant
4:34pm
8-K
92wb73nx6le0 ekcgi2
1 Jun 23
Departure of Directors or Certain Officers
5:21pm